GW Pharmaceuticals Plc
(NASDAQ : GWPH)

( )
GWPH PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corp. Plc 1.19%5.101.6%$115.59m
VRXValeant Pharmaceuticals International, Inc. 1.51%14.8414.1%$87.32m
PRGOPerrigo Co. Plc 0.36%47.216.8%$84.16m
JAZZJazz Pharmaceuticals Plc -0.52%105.222.3%$81.91m
CTLTCatalent, Inc. 0.53%52.672.2%$74.40m
ICLRICON plc -0.74%144.004.2%$71.51m
UTHRUnited Therapeutics Corp. -0.73%95.0614.3%$71.27m
HZNPHorizon Therapeutics Plc -3.76%30.766.5%$70.40m
AXSMAxsome Therapeutics, Inc. -0.14%49.801.9%$60.95m
GWPHGW Pharmaceuticals Plc 2.32%93.856.2%$59.28m
ICPTIntercept Pharmaceuticals, Inc. 0.10%62.9116.8%$42.33m
SAGESAGE Therapeutics, Inc. -0.10%29.008.6%$41.04m
PBHPrestige Consumer Healthcare, Inc. -1.89%38.434.0%$34.26m
PCRXPacira Biosciences, Inc. 1.97%32.6310.4%$30.74m
MYOKMyoKardia, Inc. -1.79%47.192.1%$25.98m

Company Profile

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.